Literature DB >> 17189289

Human SULT1A1 gene: copy number differences and functional implications.

Scott J Hebbring1, Araba A Adjei, Janel L Baer, Gregory D Jenkins, Jianping Zhang, Julie M Cunningham, Daniel J Schaid, Richard M Weinshilboum, Stephen N Thibodeau.   

Abstract

SULT1A1, which catalyzes the sulfate conjugation of a wide variety of natural and synthetic compounds, is genetically polymorphic. Biochemical and pharmacogenetic studies have demonstrated that individual variation in the level of enzyme activity is inherited. Common single-nucleotide polymorphisms (SNPs) located in the open reading frame and in the 5'-flanking region (5'-FR) may account for a portion of this individual variation. In this study, we demonstrate the presence of SULT1A1 gene deletions and duplications, representing an additional source of variability in the metabolic activity of this enzyme. A quantitative multiplex PCR assay was used to measure the extent of copy number differences and the frequency of these events in different populations. An analysis of DNA from 362 Caucasian-American and 99 African-American showed the presence of 1 to approximately 5 copies of SULT1A1 in individual samples: 5% of Caucasian subjects contained a single copy of the gene and 26% had three or more copies, while 63% of African-American subjects had three or more copies. Analysis of the genomic region surrounding the SULT1A1 gene in three separate cases with a deletion demonstrated that the entire SULT1A1 gene was affected. Reporter assays, constructed for each of the various 5'-FR SNP haplotypes, suggest that these may also play a role in SULT1A1 activity. However, the variability in the level of enzyme activity among 23 human platelet and 267 human liver samples was best explained by gene copy number differences when all sources of genetic variability were considered (P < 0.0001). Overall, these observations have obvious implications for the effectiveness of SULT1A1 as a drug and hormone metabolizing enzyme and its potential role as a risk factor for disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17189289     DOI: 10.1093/hmg/ddl468

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  47 in total

1.  SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen.

Authors:  Ann M Moyer; Vera J Suman; Richard M Weinshilboum; Rajeswari Avula; John L Black; Stephanie L Safgren; Mary J Kuffel; Matthew M Ames; James N Ingle; Matthew P Goetz
Journal:  Pharmacogenomics       Date:  2011-10-03       Impact factor: 2.533

Review 2.  Sulfotransferase gene copy number variation: pharmacogenetics and function.

Authors:  S J Hebbring; A M Moyer; R M Weinshilboum
Journal:  Cytogenet Genome Res       Date:  2009-03-11       Impact factor: 1.636

3.  Genetic variation, expression and ontogeny of sulfotransferase SULT2A1 in humans.

Authors:  L Ekström; A Rane
Journal:  Pharmacogenomics J       Date:  2015-03-24       Impact factor: 3.550

4.  Multi-ethnic SULT1A1 copy number profiling with multiplex ligation-dependent probe amplification.

Authors:  Raymon Vijzelaar; Mariana R Botton; Lisette Stolk; Suparna Martis; Robert J Desnick; Stuart A Scott
Journal:  Pharmacogenomics       Date:  2018-05-23       Impact factor: 2.533

Review 5.  Genetics of cardiovascular disease: Importance of sex and ethnicity.

Authors:  Stacey J Winham; Mariza de Andrade; Virginia M Miller
Journal:  Atherosclerosis       Date:  2015-03-16       Impact factor: 5.162

6.  Relationship of SULT1A1 copy number variation with estrogen metabolism and human health.

Authors:  Jixia Liu; Ran Zhao; Zhan Ye; Alexander J Frey; Emily R Schriver; Nathaniel W Snyder; Scott J Hebbring
Journal:  J Steroid Biochem Mol Biol       Date:  2017-09-01       Impact factor: 4.292

7.  Pharmacogenetics of SULT1A1.

Authors:  Jaclyn Daniels; Susan Kadlubar
Journal:  Pharmacogenomics       Date:  2014-11       Impact factor: 2.533

8.  Congress on women's health Trudy Bush lecture 2014: new insights into sex Hormones and Cardiovascular disease.

Authors:  Virginia M Miller
Journal:  J Womens Health (Larchmt)       Date:  2014-12       Impact factor: 2.681

9.  Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer.

Authors:  Jennifer Gjerde; Jürgen Geisler; Steinar Lundgren; Dagfinn Ekse; Jan Erik Varhaug; Gunnar Mellgren; Vidar M Steen; Ernst A Lien
Journal:  BMC Cancer       Date:  2010-06-21       Impact factor: 4.430

10.  Copy number variation and cytidine analogue cytotoxicity: a genome-wide association approach.

Authors:  Krishna R Kalari; Scott J Hebbring; High Seng Chai; Liang Li; Jean-Pierre A Kocher; Liewei Wang; Richard M Weinshilboum
Journal:  BMC Genomics       Date:  2010-06-04       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.